The DOI matches its Crossref record; 157 of the 159 references it cites were found in a registry or an index.
TIM3 comes of age as an inhibitory receptor
Open accessAbstract
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and CD8+ T cells. Initial data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the lack of a definable inhibitory signalling motif, it was also suggested that TIM3 might act as a co-stimulatory receptor. Recent studies have shown that TIM3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which are co-expressed and co-regulated on dysfunctional or 'exhausted' T cells in chronic viral infections and cancer. Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell responses in patients with advanced cancers. Here, we highlight the developments in understanding TIM3 biology, including novel ligand identification and the discovery of loss-of-function mutations associated with human disease. In addition, we summarize emerging data from human clinical trials showing that TIM3 indeed acts as a 'checkpoint' receptor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, tyrosine kinase FYN and human leukocyte antigen B (HLA‐B)‐associated transcript 3 (BAT3) were suggested to inhibit the cytoplasmic tail of TIM‐3 signaling [307, 308, 309].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [307]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the latter of which encodes the checkpoint molecule TIM3, one of the most promising new therapeutic approaches in cancer 32 that was recently described in a GWAS as an AD risk gene 2 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationMiller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citationDefining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,677
Self-citationKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Self-citationImmunogenic death of colon cancer cells treated with oxaliplatin
Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,224
Identification of Tim4 as a phosphatidylserine receptor
Miyanishi, M., Tada, K., Koike, M., Uchiyama, Y., Kitamura, T., & Nagata, S. (2007) · Nature · doi:10.1038/nature06307 · Cited by 1,180
Notch–RBP-J signaling controls the homeostasis of CD8− dendritic cells in the spleen
Caton, M. L., Smith-Raska, M., & Reizis, B. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062648 · Cited by 870
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Self-citationChiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838
Jones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C. Y., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 768
Fueyo, A. S., Tian, J. Y., Picarella, D., Domenig, C. M., Zheng, X. X., Sabatos, C. A., Manlongat, N., Bender, O., Kamradt, T., Kuchroo, V. K., et al. (2003) · Nature Immunology · doi:10.1038/ni987 · Cited by 721
Self-citationCEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717
Self-citationPromotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
Anderson, A. C., Anderson, D. E., Bregoli, L., Hastings, W. D., Kassam, N., Lei, C., Chandwaskar, R., Kármán, J., Su, E. W., Hirashima, M., et al. (2007) · Science · doi:10.1126/science.1148536 · Cited by 703
Self-citationCD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 679
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Self-citationTIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells
Kobayashi, N., Karisola, P., Peña‐Cruz, V., Dorfman, D. M., Jinushi, M., Umetsu, S. E., Butte, M. J., Nagumo, H., Chernova, I., Zhu, B., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.011 · Cited by 669
Effects of glycosylation on the stability of protein pharmaceuticals
Solá, R. J., & Griebenow, K. H. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21504 · Cited by 643
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Wu, T., Ji, Y., Moseman, E. A., Xu, H. C., Manglani, M., Kirby, M., Anderson, S. M., Handon, R., Kenyon, E., Elkahloun, A. G., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai8593 · Cited by 639
Sabatos, C. A., Chakravarti, S., Cha, E., Schubart, A., Fueyo, A. S., Zheng, X. X., Coyle, A. J., Strom, T. B., Freeman, G. J., & Kuchroo, V. K. (2003) · Nature Immunology · doi:10.1038/ni988 · Cited by 638
Self-citationCheckpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia, J., Rozenblatt-Rosen, O., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.014 · Cited by 636
Self-citationFreeman, G. J., Casasnovas, J. M., Umetsu, D. T., & DeKruyff, R. H. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00903.x · Cited by 630
Effect of glycosylation on protein folding: A close look at thermodynamic stabilization
Shental-Bechor, D., & Levy, Y. (2008) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0801340105 · Cited by 596
Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita∥, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 588
CEACAM1: contact-dependent control of immunity
Gray‐Owen, S. D., & Blumberg, R. S. (2006) · Nature reviews. Immunology · doi:10.1038/nri1864 · Cited by 540
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Ndhlovu, L. C., López‐Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C., Fujita, T., Nixon, D. F., & Lanier, L. L. (2012) · Blood · doi:10.1182/blood-2011-11-392951 · Cited by 512
Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family
McIntire, J. J., Umetsu, S. E., Akbari, O., Potter, M., Kuchroo, V. K., Barsh, G. S., Freeman, G. J., Umetsu, D. T., & DeKruyff, R. H. (2001) · Nature Immunology · doi:10.1038/ni739 · Cited by 501
Self-citationLi, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Kikushige, Y., Shima, T., Takayanagi, S., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T. T., Inagaki, Y., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.11.014 · Cited by 492
T-Cell Lymphoma Involving Subcutaneous Tissue
Gonzalez, C. L., Medeiros, L. J., Braziel, R. M., & Jaffe, E. S. (1991) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199101000-00002 · Cited by 462
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.
Nakayama, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M., Yagita, H., & Okumura, K. (2009) · Blood · doi:10.1182/blood-2008-10-185884 · Cited by 446
Induction and transcriptional regulation of the co-inhibitory gene module in T cells
Chihara, N., Madi, A., Kondo, T., Zhang, H., Acharya, N., Singer, M., Nyman, J., Marjanovic, N. D., Kowalczyk, M. S., Wang, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0206-z · Cited by 438
Self-citationReversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jiménez-Baranda, S., Khan, S. A., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 436
Self-citationGolden‐Mason, L., Palmer, B. E., Kassam, N., Townshend‐Bulson, L., Livingston, S., McMahon, B. J., Castelblanco, N., Kuchroo, V. K., Gretch, D. R., & Rosen, H. R. (2009) · Journal of Virology · doi:10.1128/jvi.00639-09 · Cited by 431
Self-citationGao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Fengming, W., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 418
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E. A., Sobel, R. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2871 · Cited by 394
Self-citationTIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Gleason, M., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M., Cooley, S., Verneris, M. R., Cichocki, F. M., Holman, C., Panoskaltsis‐Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 383
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
Curtin, J. F., Liu, N., Candolfi, M., Xiong, W., Assi, H. H., Yagiz, K., Edwards, M. R., Michelsen, K. S., Kroeger, K. M., Liu, C., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000010 · Cited by 362
Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells
Wu, C., Thalhamer, T., França, R. F. D. O., Xiao, S., Wang, C., Hotta, C., Zhu, C. Y., Hirashima, M., Anderson, A. C., & Kuchroo, V. K. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.011 · Cited by 358
Self-citationCoexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 351
DeKruyff, R. H., Bu, X., Ballesteros, Á., Santiago, C. A., Chim, Y.-L., Lee, H., Karisola, P., Pichavant, M., Kaplan, G. G., Umetsu, D. T., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903059 · Cited by 342
TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C. (2013) · OncoImmunology · doi:10.4161/onci.23849 · Cited by 340
Self-citationBrummelman, J., Mazza, E. M. C., Alvisi, G., Colombo, F. S., Grilli, A., Mikulak, J., Mavilio, D., Alloisio, M., Ferrari, F., Lopci, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180684 · Cited by 334
TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
Hastings, W. D., Anderson, D. E., Kassam, N., Koguchi, K., Greenfield, E. A., Kent, S. C., Zheng, X. X., Strom, T. B., Hafler, D. A., & Kuchroo, V. K. (2009) · European Journal of Immunology · doi:10.1002/eji.200939274 · Cited by 333
Self-citationJan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., & Majeti, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100551108 · Cited by 321
McMahan, R. H., Golden‐Mason, L., Nishimura, M. I., McMahon, B. J., Kemper, M., Allen, T. M., Gretch, D. R., & Rosen, H. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43127 · Cited by 313
Kikushige, Y., Miyamoto, T., Yuda, J., Jabbarzadeh‐Tabrizi, S., Shima, T., Takayanagi, S., Niiro, H., Yurino, A., Miyawaki, K., Takenaka, K., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.07.011 · Cited by 288
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Lee, J., Su, E. W., Zhu, C., Hainline, S., Phuah, J., Moroco, J. A., Smithgall, T. E., Kuchroo, V. K., & Kane, L. P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05297-11 · Cited by 285
Self-citationTim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Dardalhon, V., Anderson, A. C., Kármán, J., Apétoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903275 · Cited by 278
Self-citationNebbia, G., Peppa, D., Schurich, A., Khanna, P., Singh, H. D., Cheng, Y., Rosenberg, W. M., Dusheiko, G. M., Gilson, R. J. C., Chin‐Aleong, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047648 · Cited by 276
Silva, I. G., Yasinska, I. M., Sakhnevych, S. S., Fiedler, W., Wellbrock, J., Bardelli, M., Varani, L., Hussain, R., Siligardi, G., Ceccone, G., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.07.018 · Cited by 236
Dysregulated T cell expression of TIM3 in multiple sclerosis
Koguchi, K., Anderson, D. E., Yang, L., O’Connor, K. C., Kuchroo, V. K., & Hafler, D. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060210 · Cited by 232
Self-citationCao, E., Zang, X., Ramagopal, U. A., Mukhopadhaya, A., Fedorov, A. A., Fedorov, E. V., Zencheck, W. D., Lary, J. W., Cole, J. L., Deng, H., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.016 · Cited by 231
The TIM gene family regulates autoimmune and allergic diseases
Meyers, J. H., Sabatos, C. A., Chakravarti, S., & Kuchroo, V. K. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.008 · Cited by 219
Self-citationGayden, T., Sepulveda, F. E., Khuong-Quang, D.-A., Pratt, J., Valera, E. T., Garrigue, A., Kelso, S., Sicheri, F., Mikael, L. G., Hamel, N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0251-4 · Cited by 218
Khademi, M., Illés, Z., Gielen, A. W., Marta, M., Takazawa, N., Baecher‐Allan, C., Brundin, L., Hannerz, J., Martin, C., Harris, R. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.7169 · Cited by 217
Self-citationJayaraman, P., Sada‐Ovalle, I., Nishimura, T., Anderson, A. C., Kuchroo, V. K., Remold, H. G., & Behar, S. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202688 · Cited by 217
Self-citationFourcade, J. J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B. M., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 216
Self-citationAn IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction
Zhu, C. Y., Sakuishi, K., Xiao, S., Sun, Z., Zaghouani, S., Gu, G., Wang, C., Tan, D. J., Wu, C., Rangachari, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7072 · Cited by 208
Self-citationTim3 binding to galectin-9 stimulates antimicrobial immunity
Jayaraman, P., Sada‐Ovalle, I., Beladi, S., Anderson, A. C., Dardalhon, V., Hotta, C., Kuchroo, V. K., & Behar, S. M. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100687 · Cited by 201
Self-citationA highly conserved tyrosine of Tim‐3 is phosphorylated upon stimulation by its ligand galectin‐9
van de Weyer, P. S., Muehlfeit, M., Klose, C., Bonventre, J. V., Walz, G., & Kuehn, E. W. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.079 · Cited by 198
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Yan, J., Zhang, Y., Zhang, J., Liang, J., Li, L., & Zheng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058006 · Cited by 188
Avery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 171
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y., Chiang, J., Hsu, C.-Y., Huang, C., Su, W., Chu, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 169
TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells
Nakae, S., Iikura, M., Suto, H., Akiba, H., Umetsu, D. T., DeKruyff, R. H., Saito, H., & Galli, S. J. (2007) · Blood · doi:10.1182/blood-2006-11-058800 · Cited by 168
Li, Y., Zhou, W., Yu, T., Wang, S., Jiang, Y.-L., Zhang, D., Piao, H., Fu, Q., Li, D., & Du, M. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.126 · Cited by 166
Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes
Zhang, Y., Cheng, J., Wang, J. M., Xiao, J., Wu, X. Y., Moorman, J. P., & Yao, Z. Q. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1010591 · Cited by 149
Engineering therapeutic bispecific antibodies using CrossMab technology
Klein, C., Schäfer, W. M., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2018) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 148
Lack of TIM-3 Immunoregulation in Multiple Sclerosis
Yang, L., Anderson, D. E., Kuchroo, J. R., & Hafler, D. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4409 · Cited by 142
TIM-3 Is Expressed in Melanoma Cells and Is Upregulated in TGF-Beta Stimulated Mast Cells
Wiener, Z., Kőhalmi, B., Pócza, P., Jeager, J., Tölgyesi, G., Tóth, S., Görbe, É., Papp, Z., & Falus, A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700616 · Cited by 142
The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia
Koh, H. S., Chang, C. Y., Jeon, S.-B., Yoon, H. J., Ahn, Y.-H., Kim, H.-S., Kim, I.-H., Jeon, S. H., Johnson, R. S., & Park, E. J. (2015) · Nature Communications · doi:10.1038/ncomms7340 · Cited by 141
Möller‐Hackbarth, K., Dewitz, C., Schweigert, O., Trad, A., Garbers, C., Rose‐John, S., & Scheller, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.488478 · Cited by 141
Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation
Loschko, J., Schreiber, H. A., Rieke, G. J., Esterházy, D., Meredith, M. M., Pedicord, V. A., Yao, K.-H., Caballero, S., Pamer, E. G., Mucida, D., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160062 · Cited by 140
Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs
Gupta, S., Thornley, T. B., Gao, W., Larocca, R., Turka, L. A., Kuchroo, V. K., & Strom, T. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45138 · Cited by 139
Self-citationT Cell Ig Mucin-3 Promotes Homeostasis of Sepsis by Negatively Regulating the TLR Response
Yang, X., Jiang, X., Chen, G., Xiao, Y., Geng, S., Kang, C., Zhou, T., Li, Y., Guo, X., He, X., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202661 · Cited by 139
Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection
Elahi, S., Niki, T., Hirashima, M., & Horton, H. (2012) · Blood · doi:10.1182/blood-2011-11-389585 · Cited by 135
Clayton, K. L., Haaland, M. S., Douglas-Vail, M. B., Mujib, S., Chew, G. M., Ndhlovu, L. C., & Ostrowski, M. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302663 · Cited by 134
Pincus, L. B., LeBoit, P. E., McCalmont, T. H., Ricci, R., Buzio, C., Fox, L. P., Oliver, G. F., & Cerroni, L. (2009) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181a84f32 · Cited by 133
Liu, J., Wu, L., Yang, L., Deng, W., Mao, L., Wu, H., Zhang, W., & Sun, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0713-7 · Cited by 133
Liu, J., Zhang, S., Hu, Y., Yang, Z., Li, J. P., Liu, X., Deng, L., Wang, Y., Zhang, X., Jiang, T., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000122 · Cited by 127
Wang, F., He, W., Zhou, H., Jin, Y., Wu, K., Xu, L., & Chen, Z. K. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2008.01.006 · Cited by 125
T‐bet, a Th1 transcription factor regulates the expression of Tim‐3
Anderson, A. C., Lord, G. M., Dardalhon, V., Lee, D. H., Sabatos-Peyton, C. A., Glimcher, L. H., & Kuchroo, V. K. (2010) · European Journal of Immunology · doi:10.1002/eji.200939842 · Cited by 123
Self-citationGalectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner
Oomizu, S., Arikawa, T., Niki, T., Kadowaki, T., Ueno, M., Nishi, N., Yamauchi, A., & Hirashima, M. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.01.004 · Cited by 122
Sabatos-Peyton, C. A., Nevin, J. T., Brock, A., Venable, J. D., Tan, D. J., Kassam, N., Xu, F., Taraszka, J. A., Wesemann, L. D., Pertel, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1385690 · Cited by 118
Self-citationLi, Y., Zhang, J., Zhang, D., Hong, X., Yu, T., Wang, S., Xu, Y., Piao, H., Yin, W., Yu, M., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aah4323 · Cited by 113
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
Phong, B. L., Avery, L., Sumpter, T. L., Gorman, J. V., Watkins, S. C., Colgan, J. D., & Kane, L. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150388 · Cited by 110
Galectin-9 regulates T helper cell function independently of Tim-3
Su, E. W., Bi, S., & Kane, L. (2010) · Glycobiology · doi:10.1093/glycob/cwq214 · Cited by 109
Jiang, X., Zhou, T., Xiao, Y., Yu, J., Dou, S., Chen, G., Wang, R., He, X., Hou, C., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1211219 · Cited by 106
Takamura, S., Tsuji-Kawahara, S., Yagita∥, H., Akiba, H., Sakamoto, M., Chikaishi, T., Kato, M., & Miyazawa, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903478 · Cited by 105
Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma
Polprasert, C., Takeuchi, Y., Kakiuchi, N., Yoshida, K., Assanasen, T., Sitthi, W., Bunworasate, U., Pirunsarn, A., Wudhikarn, K., Lawasut, P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028340 · Cited by 105
Zhang, Y., Cai, P., Liang, T., Wang, L., & Hu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.15954 · Cited by 104
Zhu, L., Li, N., Li, F., Zhou, Z.-H., Sang, J., Chen, Y., Han, Q., Lv, Y., & Liu, Z. (2016) · Medicine · doi:10.1097/md.0000000000005749 · Cited by 99
Immune Checkpoint Molecules in Reproductive Immunology
Mikó, É., Meggyes, M., Doba, K., Barakonyi, A., & Szereday, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00846 · Cited by 99
Leung, N., Turbide, C., Olson, M., Marcus, V., Jothy, S., & Beauchemin, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209541 · Cited by 95
Qiu, Y., Chen, J., Liao, H., Zhang, Y., Wang, H., Li, S., Luo, Y., Fang, D., Li, G., Zhou, B., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002984 · Cited by 94
Kammerer, R., Stober, D., Singer, B. B., Öbrink, B., & Reimann, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6537 · Cited by 92
Liu, Y., Shu, Q., Gao, L.-F., Hou, N., Zhao, D., Liu, X., Zhang, X., Xu, L.-Y., Yue, X.-T., Zhu, F., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.07.012 · Cited by 92
Clayton, K., Douglas-Vail, M. B., Rahman, A. K. M. N.-U., Medcalf, K. E., Xie, I. Y., Chew, G. M., Tandon, R., Lanteri, M. C., Norris, P. J., Deeks, S. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00006-15 · Cited by 92
Sun, J., Yang, M., Ban, Y., Gao, W., Song, B., Wang, Y., Zhang, Y., Shao, Q., Kong, B., & Qu, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147186 · Cited by 92
Sada‐Ovalle, I., Chávez‐Galán, L., Torre-Bouscoulet, L. I., Nava-Gamiño, L., Barrera, L., Jayaraman, P., Torres, M., Salazar-Lezama, M. Á., & Behar, S. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200990 · Cited by 91
TIM-3 Does Not Act as a Receptor for Galectin-9
Leitner, J. M., Rieger, A., Pickl, W. F., Zlabinger, G. J., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003253 · Cited by 90
PAG-Associated FynT Regulates Calcium Signaling and Promotes Anergy in T Lymphocytes
Davidson, D., Schraven, B. L., & Veillette, A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01983-06 · Cited by 88
A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease
Hansen, J. A., Hanash, S., Tabellini, L., Baik, C., Lawler, R. L., Grogan, B. M., Storer, B. E., Chin, A. P., Johnson, M. M., Wong, C., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.06.011 · Cited by 88
Harding, J. J., Patnaik, A., Moreno, V., Stein, M. N., Jankowska, A. M., de Mendizábal, N. V., Liu, Z. T., Koneru, M., & Calvo, E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.12 · Cited by 86
Human Pregnancy Up-Regulates Tim-3 in Innate Immune Cells for Systemic Immunity
Zhao, J., Zhang, L., Liu, Y., Li, B., Zhang, L., Fang, H., Song, C., Wang, X., Zhang, G., Feng, Z., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803876 · Cited by 81
Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
Xu, B., Yuan, L., Gao, Q., Yuan, P., Zhao, P., Yuan, H., Fan, H., Li, T., Qin, P., Han, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4112 · Cited by 80
Wu, W., Shi, Y., Li, J., Chen, F., Chen, Z. J., & Zheng, M. (2011) · Virology Journal · doi:10.1186/1743-422x-8-113 · Cited by 78
Galectin‐9: Diverse roles in hepatic immune homeostasis and inflammation
Golden‐Mason, L., & Rosen, H. R. (2017) · Hepatology · doi:10.1002/hep.29106 · Cited by 77
Coutelier, J., Godfraind, C., Dveksler, G. S., Wysocka, M., Cardellichio, C. B., Noël, H., & Holmes, K. V. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240622 · Cited by 76
Astrocyte galectin-9 potentiates microglial TNF secretion
Steelman, A. J., & Li, J. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0144-0 · Cited by 75
Co-Signaling Molecules in Maternal–Fetal Immunity
Xu, Y., Wang, S., Li, D., & Du, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.11.001 · Cited by 69
Ju, Y., Hou, N., Zhang, X., Zhao, D., Liu, Y., Wang, J., Luan, F., Shi, W., Zhu, F., Sun, W., et al. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.5 · Cited by 67
Lee, S. Y., & Goverman, J. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300083 · Cited by 65
Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1 polarization of macrophages
Jiang, X., Yu, J., Shi, Q., Xiao, Y., Wang, W., Chen, G., Zhao, Z. J., Wang, R., He, X., Hou, C., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.07.008 · Cited by 62
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
Kikushige, Y., & Miyamoto, T. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1433-6 · Cited by 61
TIM polymorphisms—genetics and function
Lee, J., Phong, B. L., Egloff, A. M., & Kane, L. (2011) · Genes and Immunity · doi:10.1038/gene.2011.75 · Cited by 57
Mattiuz, R., Wohn, C., Ghilas, S., Ambrosini, M., Alexandre, Y. O., Sanchez, C., Fries, A., Manh, T. V., MALISSEN, B., Dalod, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02805 · Cited by 55
Wang, X., Cao, Z., Jiang, J., Li, Y., Dong, M., Ostrowski, M., & Cheng, X. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.02.013 · Cited by 54
CEACAM1+ myeloid cells control angiogenesis in inflammation
Horst, A. K., Bickert, T., Brewig, N., Ludewig, P., van Rooijen, N., Schumacher, U., Beauchemin, N., Ito, W. D., Fleischer, B., Wagener, C., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184556 · Cited by 54
Gandhi, A. K., Kim, W. M., Sun, Z.-Y. J., Huang, Y., Bonsor, D. A., Sundberg, E. J., Kondo, Y., Wagner, G., Kuchroo, V. K., Petsko, G. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35754-0 · Cited by 53
Self-citationShi, F., Guo, X., Jiang, X., Zhou, P., Xiao, Y., Zhou, T., Chen, G., Zhao, Z. J., He, X., Hou, C., et al. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.09.001 · Cited by 52
Ju, Y., Shang, X., Liu, Z., Zhang, J., Li, Y., Shen, Y., Liu, Y., Liu, C., Liu, B., Xu, L., et al. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.001 · Cited by 51
Impaired Expression of Tim-3 on Th17 and Th1 Cells in Psoriasis
Kanai, Y., Satoh, T., Igawa, K., & Yokozeki, H. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1285 · Cited by 51
The association of TIM-3 gene polymorphism with atopic disease in Korean population
Chae, S., Park, Y., Lee, Y., Lee, J.-H., & Chung, H. (2004) · Human Immunology · doi:10.1016/j.humimm.2004.07.002 · Cited by 50
CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection
Khairnar, V., Duhan, V., Patil, A., Zhou, F., Bhat, H., Thöns, C., Sharma, P., Adomati, T., Friendrich, S.-K., Bezgovsek, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04832-2 · Cited by 49
Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease
Li, X., Chen, G., Li, Y., Wang, R., Wang, L., Lin, Z., Gao, X., Feng, J., Yuan-fang Ma, A., Shen, B., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.012 · Cited by 48
Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia
Kikushige, Y., & Miyamoto, T. (2015) · Oncology · doi:10.1159/000431062 · Cited by 48
Henao-Tamayo, M. I., Irwin, S. M., Shang, S., Ordway, D. J., & Orme, I. M. (2011) · Tuberculosis · doi:10.1016/j.tube.2011.04.001 · Cited by 48
Phong, B. L., Avery, L., Menk, A. V., Delgoffe, G. M., & Kane, L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601150 · Cited by 48
Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Ge, W., Li, J., Fan, W., Xu, D., & Sun, S. (2017) · Tumor Biology · doi:10.1177/1010428317715643 · Cited by 45
Tong, D., Zhou, Y., Chen, W., Deng, Y., Li, L., Jia, Z., & Qi, D. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1862-y · Cited by 43
Meggyes, M., Lajko, A., Palkovics, T., Totsimon, A., Illés, Z., Szereday, L., & Mikó, É. (2015) · Placenta · doi:10.1016/j.placenta.2015.07.124 · Cited by 43
A role for the TIM‐3/GAL‐9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis
Saresella, M., Piancone, F., Marventano, I., Rosa, F. L., Tortorella, P., Caputo, D., Rovaris, M., & Clerici, M. (2014) · The FASEB Journal · doi:10.1096/fj.14-258194 · Cited by 42
Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2
Wang, Z., Sun, D., Chen, G., Li, G., Dou, S., Wang, R., He, X., Hou, C., Li, Y., Feng, J., et al. (2017) · Scientific Reports · doi:10.1038/srep42095 · Cited by 42
Cyktor, J. C., Carruthers, B., Beamer, G., & Turner, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058612 · Cited by 37
Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
Murtaza, A., Laken, H., Correia, J. D. S., McNeeley, P. A., Altobell, L. J., Zhang, J., Vancutsem, P. M., Wilcoxen, K., & Jenkins, D. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32903-3 · Cited by 34
Bai, J., Li, X., Tong, D., Shi, W., Song, H., & Li, Q. (2013) · Tumor Biology · doi:10.1007/s13277-012-0610-1 · Cited by 31
Microglia activity modulated by T cell Ig and mucin domain protein 3 (Tim-3)
Wang, H., Zhu, X., Qin, L., Qian, H.-J., & Wang, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.005 · Cited by 26
Cai, C., Wang, L., Wu, Z., Li, M.-Y., Chen, W., & Sun, Y. (2012) · DNA and Cell Biology · doi:10.1089/dna.2012.1625 · Cited by 25
Genetic Alterations and Expression Pattern of CEACAM1 in Colorectal Adenomas and Cancers
Song, J. H., Cao, Z., Yoon, J. H., Nam, S. W., Kim, S. Y., Lee, J. Y., & Park, W. S. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9282-6 · Cited by 21
Waight, J. D., Iyer, P., Breous-Nystrom, E., Riordan, C., Findeis, M. A., Underwood, D. J., Connolly, J., Sanicola-Nadel, M., Nastri, H. G., Scherle, P., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3825 · Cited by 19
Quantitative assessment of TIM-3 polymorphisms and cancer risk in Chinese Han population
Gao, X., Yang, J., He, Y., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8157 · Cited by 18
Lindsted, T., Gad, M., Grandal, M. V., Frölich, C., Bhatia, V. K., Gjetting, T., Lantto, J., Horak, I. D., Kragh, M., Koefoed, K., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5629 · Cited by 18
Human disease mutations highlight the inhibitory function of TIM-3
Dixon, K. O., Das, M., & Kuchroo, V. K. (2018) · Nature Genetics · doi:10.1038/s41588-018-0289-3 · Cited by 18
Self-citationLi, S., Ren, Y., Peng, D., Yuan, Z., Shan, S., Sun, H., Yan, X., Xiao, H., Li, G., & Song, H. (2015) · Inflammation · doi:10.1007/s10753-015-0164-7 · Cited by 11
Zhang, T., Liu, X., Zhang, J., Liu, Q., Ma, J., Zhang, Y., Shi, Y., Hou, H., Peng, H. F., Liu, N., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2628 · Cited by 10
Ahn, M.-J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.194 · Cited by 8
Research works printed but not linked: 2
- Weiss, G. J. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J. Immunother. Cancer 5, 86 (2017).
- Davar, D. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J. Immunother. Cancer 6, 115 (2018).
Cited by
Sorted by citations
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C., Eghbali, S. Z., Wolchok, J. D., & Merghoub, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 885
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 768
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 738
Yang, R., Sun, L., Li, C.-F., Wang, Y.-H., Yao, J., Li, H., Yan, M., Chang, W., Hsu, J.-M., Cha, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21099-2 · Cited by 656
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Metadata
- Authors
- Wolf, Y., Anderson, A. C., & Kuchroo, V. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kuchroo, Vijay K.
- Venue
- Nature Reviews Immunology
- Published
- 2019-11-01
- Volume
- 20
- Issue
- 3
- Pages
- 173-185
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7327798
- OpenAlex
- W2985205513
- Cited by
- 959
- References
- 159
- Citations by year
- 2026: 98 · 2025: 140 · 2024: 191 · 2023: 160 · 2022: 183 · 2021: 142 · 2020: 44
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA187975)
- National Institute of Allergy and Infectious Diseases (P01AI073748, P01AI056299, P01AI039671)
- National Institute of Neurological Disorders and Stroke (R01NS045937)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- TIM-3, inhibitory receptors, co-inhibitory receptors, immune checkpoint, T cell exhaustion, loss-of-function mutations, antitumor immunity, chronic viral infection, cancer immunotherapy
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Clinical Trials as Topic, Humans, Signal Transduction, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
